DDrare: Database of Drug Development for Rare Diseases

48. 原発性抗リン脂質抗体症候群　［臨床試験数：3，薬物数：2（DrugBank：1），標的遺伝子数：0，標的パスウェイ数：0］

Searched query = "Primary antiphospholipid syndrome", "Primary antiphospholipid antibody syndrome"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Drug = Epa and dha supplementation; Hydroxychloroquine

No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03540810	August 15, 2018	11 June 2018	Hydroxychloroquine Versus Placebo: Impact on Thrombotic Relapse in Primary Antiphospholipid Syndrome	Hydroxychloroquine Versus Placebo: Impact on Thrombotic Relapse in Primary Antiphospholipid Syndrome	Primary Antiphospholipid Syndrome	Drug: Hydroxychloroquine;Drug: Placebo	University Hospital, Angers	Not recruiting	18 Years	N/A	All	300	Phase 3	France
2	NCT01956188	May 2014	16 December 2017	Omega 3 in LES and APS	Efficacy of EPA and DHA Supplementation in Systemic Lupus Erythematosus and Primary Antiphospholipid Syndrome	Systemic Lupus Erythematosus;Primary Antiphospholipid Syndrome	Dietary Supplement: EPA and DHA supplementation;Dietary Supplement: Placebo	University of Sao Paulo	Not recruiting	20 Years	45 Years	Female	22	N/A	Brazil
3	NCT04153201	January 15, 2013	11 November 2019	Hydroxychloroquine for Thrombosis Prevention and Antiphospholipid Antibody Reduction in Primary Antiphospholipid Syndrome	Effect of Hydroxychloroquine on Thrombosis Prevention and Antiphospholipid Antibody Levels in Patients With Primary Antiphospholipid Syndrome: An Pilot Randomized Prospective Study.	Antiphospholipid Syndrome	Drug: Hydroxychloroquine	National and Kapodistrian University of Athens	Not recruiting	18 Years	N/A	All	50	N/A	Greece